ERBB2 and breast carcinoma: We demonstrate that both the LCKD and the MCKD increased FA utilization, critical for ErbB2-positive breast cancer progression, and accelerated the progression of wild-type ErbB2+ tumors (Fig. 6g, Supplementary Fig. 10d, f, and Supplementary Fig. 11h, i).